Abstract:The emergence and spread of highly pathogenic avian influenza (H5N1) viruses among poultry in Asia, the Middle East, and Africa have fueled concerns of a possible human pandemic, and spurred efforts towards developing vaccines against H5N1 influenza viruses, as well as improving vaccine production methods. In recent years, promising experimental reverse genetics-derived H5N1 live attenuated vaccines have been generated and characterized, including vaccines that are attenuated through temperature-sensitive mutation, modulation of the interferon antagonist protein, or disruption of the M2 protein. Live attenuated influenza virus vaccines based on each of these modalities have conferred protection against homologous and heterologous challenge in animal models of influenza virus infection. Alternative vaccine strategies that do not require the use of live virus, such as virus-like particle (VLP) and DNA-based vaccines, have also been vigorously pursued in recent years. Studies have demonstrated that influenza VLP vaccination can confer homologous and heterologous protection from lethal challenge in a mouse model of infection. There have also been improvements in the formulation and production of vaccines following concerns over the threat of H5N1 influenza viruses. The use of novel substrates for the growth of vaccine virus stocks has been intensively researched in recent years, and several candidate cell culture-based systems for vaccine amplification have emerged, including production systems based on Madin-Darby canine kidney, Vero, and PerC6 cell lines. Such systems promise increased scalability of product, and reduced reliance on embryonated chicken eggs as a growth substrate. Studies into the use of adjuvants have shown that oil-in-water-based adjuvants can improve the immunogenicity of inactivated influenza vaccines and conserve antigen in such formulations. Finally, efforts to develop more broadly cross-protective immunization strategies through the inclusion of conserved influenza virus antigens in vaccines have led to experimental vaccines based on the influenza hemagglutinin (HA) stem domain. Such vaccines have been shown to confer protection from lethal challenge in mouse models of influenza virus infection. Through further development, vaccines based on the HA stem have the potential to protect vaccinated individuals against unanticipated pandemic and epidemic influenza virus strains. Overall, recent advances in experimental vaccines and in vaccine production processes provide the potential to lower mortality and morbidity resulting from influenza infection.

Research progress in preparation principle of live attenuated influenza H1N1 vaccine

New strategies for the development of H5N1 subtype influenza vaccines: progress and challenges

Research progress on human infection with avian influenza H7N9

Advances in Development and Application of Influenza Vaccines

Preclinical Evaluation of the Safety and Pathogenicity of a Live Attenuated Recombinant Influenza A/H7N9 Seed Strain and Corresponding MF59-adjuvanted Split Vaccine

Ns Deletions Convert The 2009-H1n1 Pandemic Virus Into A Live Attenuated Vaccine

A Chymotrypsin-Dependent Live-Attenuated Influenza Vaccine Provides Protective Immunity against Homologous and Heterologous Viruses

Preparation and evaluation of a novel, live, attenuated influenza H1N1 vaccine strain produced by a modified classical reassortment method

Progress on adenovirus-vectored universal influenza vaccines

How far have we reached in development of effective influenza vaccine?

Research Progress of Hemagglutinin Gene of Avian Influenza Virus

Attenuation of the Influenza Virus by Microrna Response Element in Vivo and Protective Efficacy Against 2009 Pandemic H1N1 Virus in Mice

Progress on 2009 H1N1 Virus and Prevention and Treatment of Influenza Pandemic

Ns-Based Live Attenuated H1n1 Pandemic Vaccines Protect Mice and Ferrets

Research Advances in Human Infection with Avian-Origin Influenza A (H7n9)virus

Development Of A New Candidate H5n1 Avian Influenza Virus For Pre-Pandemic Vaccine Production

Development and Evaluation of Vero Cell-Derived Master Donor Viruses for Influenza Pandemic Preparedness

Influenza vaccines: Past, present, and future

Progress and perspectives of universal influenza vaccine

Study on the Genomic Sequences and Molecular Characteristics of Influenza A(H1N1) Virus

Research Progress in Broad Neutralizing Antibodies and Universal Vaccines Against Influenza A Virus